INTRODUCTION

Histopathologic examination of liver tissue obtained via biopsy may provide essential diagnostic and clinical information impacting patient care.\(^1\) Traditionally, hepatic tissue specimens have been obtained via a percutaneous, transjugular, or surgical approach. Dr. Paul Ehrlich is credited with the first liver aspiration in 1883. Subsequently, both Dr. Bingle in 1923 and Dr. Menghini in 1958 implemented several modifications to the technique before becoming widely accepted.\(^1\) The transvenous approach, typically through the transjugular route, followed a few years later in 1964.\(^7\)

While advancements in medical technology, especially imaging resolution and elastography, have reduced the role of liver biopsy as standard practice for many individuals with liver disease, histologic examination of hepatic tissue is critical for staging of parenchymal liver disease, development of treatment plans based upon histologic analysis, and diagnostic evaluation of many acute and chronic liver abnormalities.\(^8\)

For a majority of patients, percutaneous liver biopsy (PCLB) remains the preferred approach since it is less invasive and low cost compared with the transjugular route.\(^6\) However, transjugular liver biopsy (TJLB) may be preferred for patients with

---

**Background/Aims:** Percutaneous liver biopsy (PCLB) or transjugular liver biopsy (TJLB) have traditionally been performed to obtain a sample of hepatic tissue; however, endoscopic ultrasound-guided liver biopsy (EUSLB) has become an attractive alternative. The aim of this study was to compare the efficacy and safety of EUSLB, PCLB, and TJLB.

**Methods:** Search strategies were developed in accordance with PRISMA and MOOSE guidelines. Major outcomes included the following: adequacy of biopsy specimens (i.e., complete portal triads [CPT], total specimen length [TSL] in mm, and length of longest piece [LLP] in mm), and rate of adverse events. Only studies comparing all biopsy approaches (i.e., EUSLB, PCLB, and TJLB) were included.

**Results:** Five studies (EUSLB \(n=301\); PCLB \(n=176\); and TJLB \(n=179\)) were included. Biopsy cumulative adequacy rates for EUSLB, PCLB, and TJLB were 93.51%, 98.27%, and 97.61%, respectively. Based on the subgroup analysis limited to EUS biopsy needles in current clinical practice, there was no difference in biopsy adequacy or adverse events for EUSLB compared to PCLB and TJLB (all \(p\) > 0.050). A comparison of EUSLB and PCLB revealed no difference between specimens regarding both CPT (\(p=0.079\)) and LLP (\(p=0.085\)); however, a longer TSL (\(p<0.001\)) was observed. Compared to TJLB, EUSLB showed no difference in LLP (\(p=0.351\)), fewer CPT (\(p=0.042\)), and longer TSL (\(p=0.005\)).

**Conclusions:** EUSLB appears to be a safe, minimally invasive procedure that is comparable to PCLB and TJLB regarding biopsy specimens obtained and rate of adverse events associated with each method. **Clin Endosc 2020;53:583-593**

**Key Words:** Endoscopic ultrasound (EUS); Interventional endoscopy; Liver biopsy
coagulopathy, large-volume ascites, or a suspected vascular tumor. TJLB is also commonly considered a potential alternative for patients in whom the percutaneous approach is suboptimal, contraindicated, or has been previously unsuccessful. The transjugular approach may also be more feasible in patients with acute liver failure with associated coagulopathy, or among patients with cirrhosis that would benefit from hepatic venous pressure gradient measurement to assess for clinically significant portal hypertension.

Endoscopic ultrasound-guided liver biopsy (EUSLB) has become an attractive alternative to percutaneous and transjugular approaches. Potential advantages of this technique include real-time imaging during the entire procedure, acquisition of liver biopsy specimens simultaneously during endosonography, greater accessibility to multiple sites (i.e., left lobe, caudate lobe, and right lobe) regardless of body habitus, improved accessibility to small liver lesions, and avoidance of invasive procedures, such as vascular puncture or catheter placement. While an EUS-guided transgastric approach offers a novel method for obtaining liver biopsies in patients undergoing upper endosonography, there is a paucity of data to compare the outcomes of various biopsy strategies. The primary aim of this study was to perform a structured systematic review and meta-analysis to compare the efficacy and safety of EUSLB, PCLB, and TJLB.

MATERIALS AND METHODS

Study design and search strategy

The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) for reporting systematic reviews and meta-analyses were followed based on an established protocol—the PRISMA and MOOSE checklists are provided as Supplementary materials 1 and 2. This study was submitted to PROSPERO, an international database of prospectively registered systematic reviews in health and social care. Individualized search strategies were developed for the following databases from inception through November 30, 2018: PubMed, EMBASE, Web of Science, and Cochrane databases. The medical subject heading (MeSH) terms included: liver biopsy. For articles related to liver biopsy, subject heading search terms and title and abstract were reviewed for the following: endoscopic ultrasound (EUS), percutaneous, transvenous, or transjugular.

All relevant articles, regardless of type, year of publication, or status (full-text manuscripts and published abstracts), were included. Based on the initial search results, the titles and abstracts of all potential studies were screened for eligibility, with references manually reviewed by cross-checking bibliographies of retrieved articles. Two reviewers (TRM and ANB) independently performed the screening process of titles and abstracts according to predefined inclusion and exclusion criteria. Any differences between TRM and ANB were resolved by mutual agreement and in consultation with a third reviewer (BN). For studies with incomplete information, primary contact was attempted with the principal authors to obtain missing data.

Study selection criteria

Randomized controlled trials and observational studies evaluating all three treatment cohorts (EUSLB, PCLB, and TJLB) were included in this analysis. For comparative review, we included studies with adults patients aged 18 and older, and studies that used all three techniques (EUSLB, PCLB, and TJLB) for hepatic sampling. Included studies were required to report at least one of the primary outcomes for study analysis. Non-human studies, or studies that only compared two modalities, were excluded. Multiple published works from similar authors were evaluated for overlapping enrollment times to preserve independence of observations, with contact of principal authors performed when needed. Studies with insufficient data, as well as study types that did not report primary or independent data, were excluded from this systematic review and meta-analysis. Case series were also not included in effort to reduce selection bias.

Endoscopic ultrasound-liver biopsy needle type

All EUSLB needle types were included for cumulative analysis. However, on subgroup analysis, only needles used in routine clinical practice were considered for inclusion. The available EUSLB needle types that were considered acceptable for subgroup analysis included the 19 G fine needle aspiration (FNA) or the fine needle biopsy (FNB)—including 19 G SharkCore FNB (Medtronic Co., Minneapolis, MN, USA), 19 G Expect FNA (Boston Scientific), 22 G SharkCore FNB, and the 19 G, 22 G, and 25 G Acquire EUS FNB needle (Boston Scientific). Based on previous comparator studies, older or first generation EUS core needles, including needles that are no longer available in clinical practice, were excluded to simulate real-world clinical practice. The excluded needle types comprised the 19 G or 22 G ProCore, 18 G QuickCore (Cook Medical), 18 G Acquire FNB needle (Medtronic Co., Minneapolis, MN, USA), and Coaxial Temno needle (Care-Fusion, McGraw Park, IL, USA).

Outcome measures

The primary outcomes of this structured systematic review and meta-analysis were adequacy of biopsy specimens for pathology review (i.e., complete portal triads [CPT], total
specimen length [TSL] in mm, and length of longest piece [LLP] in mm), and rate of adverse events. The adequacy of a liver biopsy has conventionally been defined in terms of the minimum length of the tissue cores and the presence of a minimum number of complete portal tracts (defined as at least 6 to 11 complete portal tracts for adequate diagnosis).\(^\text{1,2,22}\) Previous systematic reviews and meta-analyses of percutaneous and transjugular routes to obtain hepatic tissue have defined adequacy of liver biopsy as 7.5 CPT, with TSL of 17.7 mm, and 6.5 CPT, with TSL of 12 mm, respectively.\(^\text{10,23}\) Currently, an optimal definition of specimen adequacy for EUSLB has not yet been established. Adverse events were primarily concerned with bleeding; however, direct procedure-related complications, such as significant abdominal pain, were also included.

**Statistical analysis**

The systematic review and meta-analysis were performed using pooled proportions. Subsequently, individual study proportions were transformed into a quantity using the Freeman–Tukey variant of the arcsine square root transformed proportion. Next, pooled proportions were calculated as the back transform of the weighted mean of the transformed proportion using DerSimonian–Laird weights for the random effects model.\(^\text{24-27}\) The rates were estimated using a random effects model and then presented as point estimates (rates) with 95% confidence intervals (CIs).\(^\text{28-30}\)

Subgroup analyses were also performed based upon the comparative effectiveness of varying biopsy strategies limited to studies with EUS biopsy needles used in current clinical practice. If there were < 3 studies included, pooled proportions using a random effects model could not be calculated. In this case, non-pooled outcome measures were used to compare outcomes between different sampling strategies using two-sample \(t\)-tests for binomial proportions. All calculated \(p\)-values were 2-sided, and a \(p\)-value of < 0.05 was considered statistically significant. Tabular and graphical analyses were performing using Comprehensive Meta-Analysis software, version 3 (BioStat, Englewood, NJ, USA). Combined weighted proportions were determined by use of the Stata 15.0 software package (StataCorp LP, College Station, TX, USA).

**Risk of bias and quality assessment**

For observational studies, the risk of bias and quality were evaluated using the Newcastle–Ottawa Quality Assessment Scale. For randomized controlled trials, the JADAD score was used to determine quality.\(^\text{31,32}\) High-quality studies were defined as a Newcastle–Ottawa Quality Assessment Scale score of \(\geq 5\) or a JADAD score of \(\geq 4\). For observational studies, scores were determined by study design, full manuscript or abstract article type, cohort size, specimen collection details, histologic examination, adverse event reporting, and attrition rate similar to previously published literature.\(^\text{20}\) Risk of bias and quality of studies were assessed independently by two authors (TRM and ANB), with disagreements resolved by consultation with the third reviewer (BN).

**Investigations of heterogeneity**

Heterogeneity was assessed using the chi squared test and the \(\hat{I}^2\) statistic.\(^\text{33}\) Significant heterogeneity was defined as \(p < 0.05\) using the Cochran Q test or \(\hat{I}^2 > 50\%), with values > 50% indicating substantial heterogeneity. Based on the use of the random effects model to estimate average effect size, a 95% prediction interval was calculated to determine the dispersion of effects and clearly illustrate heterogeneity in the calculated effect size.\(^\text{28,34-36}\)

**Publication bias**

To assess publication bias, Egger regression testing was used and a funnel plot was created and visually inspected for asymmetry.\(^\text{37,38}\) The trim and fill method was used to correct for funnel plot asymmetry and to provide an adjusted effect.\(^\text{39}\) The classic fail-safe test was also applied to assess risk of bias across studies.

**RESULTS**

**Included study and patient characteristics**

Five comparator studies were included in this meta-analysis and a total of 656 patients were enrolled—EUSLB \((n = 301)\); PCLB \((n = 176)\); and TJLB \((n = 179)\).\(^\text{14,40-43}\) A PRISMA flow chart of search results is shown in Fig. 1. Three abstracts and two full-text manuscripts published between 2015 and 2018 were included in this analysis. Among the included studies, four were retrospective in design and one was prospective. The cumulative data of all studies and patient characteristics are highlighted in Table 1. The mean age of all included patients was 51.62 ± 2.81 years and 43.93% of patients were male. The adequacy rate of biopsy specimens for EUSLB was 93.51% (95% CI, 93.31 to 93.76); \(\hat{I}^2 = 88.40\%\); prediction interval –1.00 to 1.00, range 2.00; Meanwhile, for PCLB, the adequacy rate was 98.27% (95% CI, 97.69 to 99.27); \(\hat{I}^2 = 0.00\%\); prediction interval 0.68 to 1.00, range 0.32. Finally, for TJLB, the adequacy rate was 97.61% (95% CI, 96.39 to 99.16); \(\hat{I}^2 = 0.00\%\); prediction interval 0.78 to 1.00, range 0.22 (Fig. 2A-C). The cumulative data for each modality is highlighted in Supplementary Table 1.

**Comparative subgroup analyses**

In order to compare the three modalities, only EUS biopsy
needles utilized in current clinical practice were considered. Indeed, the study by Nakanishi et al. was excluded given inclusion of needle types not routinely utilized in clinical practice. Regarding adequacy of biopsy specimens, EUSLB was comparable to PCLB (98.53% vs. 100.00%, \( p = 0.410 \)) and was similar to TJLB (98.53% vs. 100.0%, \( p = 0.351 \)). Meanwhile, adverse events with EUSLB were similar to PCLB (16.46% vs. 12.24%, \( p = 0.516 \)) and to TJLB (EUS: 16.46% vs. TJLB: 4.88%, \( p = 0.071 \)).

Analysis of specimen adequacy also involved comparison of CPT, TSL, and LLP among the three modalities. A comparison of EUSLB and PCLB resulted in histologic samples with no difference in CPT (odds ratio [OR], 4.70; 95% CI, –0.54 to 9.92; \( I^2 = 79.79\% \); \( p = 0.079 \); Fig. 3A), no difference in LLP (OR, –3.34; 95% CI, –7.14 to 0.46; \( I^2 = 79.63\% \); \( p = 0.085 \); Fig. 3B), and longer TSL (OR, 11.35; 95% CI, 6.77 to 15.93; \( I^2 = 0.00\% \); \( p < 0.001 \); Fig. 3C). Meanwhile, a comparison of EUSLB and TJLB resulted in no difference in LLP (–1.92 [95% CI, –5.94 to 2.11]); \( I^2 = 82.86\% \); \( p = 0.351 \); Fig. 3B), smaller number of CPT (–1.67 [95% CI, –3.28 to –0.06]; \( I^2 = 0.00\% \); \( p = 0.042 \); Fig. 4A), smaller number of CPT (–1.67 [95% CI, –3.28 to –0.06]; \( I^2 = 0.00\% \); \( p = 0.042 \); Fig. 4B), and longer TSL (OR, 6.28; 95% CI, 1.93 to 10.63; \( I^2 = 3.94\% \); \( p = 0.005 \); Fig. 4C).

Risk of bias assessment
All 5 studies were assessed using the Newcastle–Ottawa Quality Assessment Scale, which assigned a high-quality...
Table 1. Characteristics of Included Studies to Compare Endoscopic Ultrasound-guided Liver Biopsy versus Percutaneous Liver Biopsy versus Transjugular Liver Biopsy

<table>
<thead>
<tr>
<th>Study</th>
<th>Full text or abstract</th>
<th>Study country</th>
<th>Type of study</th>
<th>No. of Pts</th>
<th>Mean age (yr)</th>
<th>No. of males</th>
<th>Needle type</th>
<th>Specimen adequacy</th>
<th>CPT</th>
<th>TSL (mm)</th>
<th>LLP (mm)</th>
<th>Adverse events</th>
<th>Quality assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endoscopic ultrasound-guided liver biopsy studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakanishi et al. (2015)</td>
<td>Full text</td>
<td>USA</td>
<td>Single-center prospective</td>
<td>113</td>
<td>50</td>
<td>29</td>
<td>19 G core biopsy needle (QuickCore, ProCore, or Expect Flex)</td>
<td>74/113</td>
<td>10.07 (16.31)</td>
<td>-</td>
<td>5.65 (4.64)</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>Pineda et al. (2016)</td>
<td>Full text</td>
<td>USA</td>
<td>Single-center retrospective</td>
<td>110</td>
<td>53</td>
<td>48</td>
<td>19 G FNA (Expect or Expect Flex)</td>
<td>108/110</td>
<td>14 (5.22)</td>
<td>38 (16.47)</td>
<td>6 (2.03)</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>Foor-Pessin et al. (2017)</td>
<td>Abstract</td>
<td>USA</td>
<td>Single-center retrospective</td>
<td>15</td>
<td>58.5</td>
<td>4</td>
<td>19 G FNA or FNB</td>
<td>15/15</td>
<td>12.53 (9.16)</td>
<td>48.6 (42.19)</td>
<td>7.5 (4.33)</td>
<td>0/15</td>
<td>6.5</td>
</tr>
<tr>
<td>Shahshahan et al. (2017)</td>
<td>Abstract</td>
<td>USA</td>
<td>Single-center retrospective</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>19 G FNA (Expect or Expect Flex)</td>
<td>11/11</td>
<td>5.9</td>
<td>-</td>
<td>-</td>
<td>0/11</td>
<td>6.5</td>
</tr>
<tr>
<td>El Chafic et al. (2018)</td>
<td>Abstract</td>
<td>USA</td>
<td>Single-center retrospective</td>
<td>52</td>
<td>53.6</td>
<td>22</td>
<td>19 G core biopsy needle (SharkCore)</td>
<td>-</td>
<td>19.36 (9.8)</td>
<td>22.95 (15.7)</td>
<td>17.24 (13.6)</td>
<td>13/53</td>
<td>6.5</td>
</tr>
</tbody>
</table>

| **Percutaneous liver biopsy studies**        |                       |               |                     |            |               |              |                                                 |                    |          |          |          |               |                   |
| Nakanishi et al. (2015)                      | Full text             | USA           | Single-center prospective | 100        | 49            | 50           | -                                               | 100/100            | 14.53 (7.8) | -        | 12.59 (3.16) | -              | 6                 |
| Pineda et al. (2016)                         | Full text             | USA           | Single-center retrospective | 27         | -             | -            | 18 G or 19 G needle                              | 27/27              | 10 (2.60) | 25 (6.64) | 10 (2.57) | -              | 6                 |
| Foor-Pessin et al. (2017)                    | Abstract              | USA           | Single-center retrospective | 15         | 57.6          | 13           | 18 G needle                                     | 15/15              | 13.73 (8.44) | 27.27 (7.16) | 14.37 (4.28) | 2/15          | 6.5               |
| Shahshahan et al. (2017)                     | Abstract              | USA           | Single-center retrospective | 14         | -             | -            | 18 G needle (Temno, Biopince, or Bard)           | 14/14              | 9.4        | -        | -        | 0/14          | 6.5               |
| El Chafic et al. (2018)                       | Abstract              | USA           | Single-center retrospective | 20         | 52.7          | 7            | 16 G biopsy needle (Monopty)                     | -                  | 9.1 (3.5)  | 14.6 (2.3) | 13.4 (2.5) | 4/20          | 6.5               |

| **Transjugular liver biopsy studies**         |                       |               |                     |            |               |              |                                                 |                    |          |          |          |               |                   |
| Nakanishi et al. (2015)                      | Full text             | USA           | Single-center prospective | 100        | 51            | 53           | -                                               | 98/100             | 11.41 (7.80) | -        | 11.36 (4.61) | -              | 6                 |
| Pineda et al. (2016)                         | Full text             | USA           | Single-center retrospective | 38         | -             | -            | 18 G or 20 G needle                              | 38/38              | 15.5 (3.45) | 34 (6.94) | 8.7 (1.94) | -              | 6                 |
| Foor-Pessin et al. (2017)                    | Abstract              | USA           | Single-center retrospective | 15         | 57.5          | 8            | 18 G needle                                     | 15/15              | 17.87 (8.61) | 31.63 (11.85) | 13.3 (4.07) | 0/15          | 6.5               |
| Shahshahan et al. (2017)                     | Abstract              | USA           | Single-center retrospective | 6          | -             | -            | 21 G needle (Temno Evolution)                    | 6/6                | 9.4        | -        | -        | 0/6           | 6.5               |
| El Chafic et al. (2018)                       | Abstract              | USA           | Single-center retrospective | 20         | 56.8          | 12           | 19 G biopsy needle (Cook)                       | -                  | 20.2 (6.9) | 14.15 (2.3) | 11.45 (2.8) | 2/20          | 6.5               |

Quality assessment as determined Newcastle–Ottawa quality assessment scale.
CPT, complete portal triads; FNA, fine needle aspiration; FNB, fine needle biopsy; LLP, length of longest piece; TSL, total specimen length.
grade (i.e., score ≥ 5) to the five studies (four retrospective and one prospective). Authors’ judgements each included study is highlighted in Table 1. Publication bias was also assessed. Visual inspection of the funnel plot for studies assessing adequacy demonstrated that smaller and statistically insignificant studies appeared to be missing likely due to publication bias (Supplementary Fig. 1A). Adequacy of EUSLB was decreased from 93.51% (95% CI, 60.41 to 99.27) to 81.94% (95% CI, 47.49 to 95.79) with Duval and Tweedie’s trim and fill method (Supplementary Fig. 1B). Using the classic fail-safe test to assess for publication bias, it was determined it would take 43 non-significant studies to nullify the results of this analysis.

**DISCUSSION**

Although the need for liver biopsy has largely been replaced in a multitude of hepatic diseases due to the availability of less invasive modalities (i.e., elastography, computed tomography, and magnetic resonance imaging), histologic examination of
hepatic tissue is still required for many diagnoses and may be pivotal to determine appropriate treatments. Based on the results of this systematic review and meta-analysis, adequacy of hepatic specimen and rate of adverse events were comparable between EUSLB, PCLB, and TJLB.

Advantages and disadvantages of endoscopic ultrasound-guided liver biopsy

Despite comparable adequacy and complication rates, the EUS technique affords many advantages over percutaneous and transjugular approaches. While PCLB and TJLB have been associated with significant variation in sample yield, EUS strategies provide high-resolution imaging and access to sampling of both lobes of the liver, which may provide a more accurate representation of liver histology and reduced sampling error. Endosonography with Doppler capability allows for the avoidance of intrahepatic vessels and real-time imaging to navigate and avoid the bowel, gallbladder, and pleural space. Most importantly, EUSLB is able to achieve these results regardless of body habitus, whereas the percutaneous

Meta analysis

Fig. 3. (A) Forest plot: comparison of complete portal triads for endoscopic ultrasound-guided liver biopsy (EUSLB) versus percutaneous liver biopsy (PCLB). (B) Forest plot: comparison of length of longest piece for EUSLB versus PCLB. (C) Forest plot: comparison of total specimen length for EUSLB versus PCLB. CI, confidence interval.
and, to a lesser extent, the transjugular routes, may be limited in obese patients. Furthermore, benefits of an EUS-guided approach include concomitant endoscopic esophageal variceal screening, gastric biopsy for *Helicobacter pylori*, and EUS imaging of the gallbladder and bile duct for evaluation of choledocholithiasis as a potential etiology of abnormal liver chemistries, in addition to the exclusion of ampullary and pancreas lesions. Despite these benefits, EUS may be limited by operator variability, requirement for deep sedation, procedure length, and associated monetary costs. However, the use of deep sedation may also beneficial, and may be appealing to the patient, reducing any morbidity, pain, or anxiety associated with the procedure.

**Evolution of endoscopic ultrasound-guided liver biopsy technique**

The first published cases of EUSLB were described in 2007 using a novel Tru-Cut core biopsy needle (QuickCore; Cook Medical, Winston Salem, NC, USA). Since the introduction of the first EUSLB, many studies have been performed to determine the preferred needle. Schulman et al. sought to assess 6 needle types: 19 G (SharkCore FNB [Medtronic],...
Adequacy of biopsy specimen

Currently, there are a variety of guidelines and recommendations that outline parameters for hepatic tissue adequacy regarding liver biopsy—each dependent upon the strategy or route of tissue acquisition. Cholangitis et al. previously performed a systematic review and meta-analysis of over 10,000 PCLBs and reported that a mean of 7.5 CPT and TSL of 17.7 mm were required for pathologic review.14 When obtained via the transjugular route, adequacy is defined as 6.5 CPT and TSL of 12 mm.10 Although an optimal definition of specimen adequacy for EUSLB has not yet been established, the American Association for the Study of Liver Diseases (AASLD) recommends ≥11 CPT as the definition of adequacy, regardless of route of sampling.6 Perhaps more importantly, the AASLD guideline also utilizes TSL > 15 mm to define adequacy, albeit it considers that the ideal size is 30 mm.8,18 Although all routes of tissue sampling in our study achieved ≥ 11 CPTs and TSL > 15 mm, only EUSLB achieved the ideal TSL of ≥ 30 mm.

Limitations and strengths

There are several limitations to this study. Although we assessed for heterogeneity as well as risk of bias, specific limitations include differences in patient population across multiple included modalities, as well as familiarity of the individual provider with the service (i.e., interventional radiology and gastroenterology) and with various techniques. Although each study evaluated all sampling techniques, there was significant heterogeneity among the included procedures (i.e., $I^2 > 50\%$) and the variety of needle types utilized. Most importantly, the lack of a formal definition of EUSLB adequacy precludes consistency across centers and pathology providers. Similarly, while our cumulative analysis included EUS needle types no longer utilized in clinical practice, the use of a standard needle type is not verified across all institutions. Additionally, due to a paucity of data, the indication for liver biopsy could not be confirmed for individual cases, thereby limiting a subgroup analysis to evaluate for changes in efficacy or safety between different indications.

Furthermore, no randomized studies were included in this analysis and only two full-text manuscripts were included, thereby potentially increasing the selection bias. As most included studies were retrospective in design, there may have been a reason for EUSLB to be performed as opposed to other sampling routes—perhaps due to body habitus or other confounders that may artificially reduce or increase the efficacy or safety of the procedure. Publication bias was present in this meta-analysis; however, with the trim and fill method, the adequacy of EUSLB decreased from 93.51% to 81.94%. Additionally, given the lack of current comparative data and expertise needed to perform EUSLB, the learning curve, or clinical acumen needed to perform an effective procedure, is unknown—thereby potentially limiting the generalizability of our findings to centers with less familiarity or proven proficiency.

Despite these limitations, this study has several strengths. Most importantly, our meta-analysis using a random effects model to methodologically summarize all available data to evaluate feasibility, efficacy, and safety of EUSLB compared to PCLB and TJLB, with an emphasis on subgroup analysis analyzing needles only commonly used in current clinical practice. Although reporting bias of negative studies cannot be verified, small case series were eliminated to minimize inherent selection bias. Additionally, this systematic review and meta-analysis evaluated objective data, including biopsy adequacy, CPT, TSL, LLP, and adverse events for all included modalities. These findings, as highlighted in our systematic review and meta-analysis, are similar to previous cumulative systematic reviews and meta-analyses of EUSLB. Mohan et al. reported a histologic diagnosis rate of 93.9% and adverse event rate of 2.3% for EUSLB.80 These authors concluded that a 19 G FNA needle provided optimal biopsy specimens. While recent published data by Diehl et al. suggests that heparin priming of EUS-FNA or FNB needles does not negatively affect cytologic or histologic interpretation, additional studies by similar authors have shown tissue adequacy to be higher for 19 G FNA versus 22 G FNB needle among patients with chronic liver disease.49,50

To date, our study is the only meta-analysis to directly compare EUSLB, PCLB, and TJLB, including data from studies that evaluated all common approaches to obtain hepatic tissue. While TJLB provides an ability to simultaneously obtain portal pressure measures, EUS may be able to do the same in the near future.51,52 In fact, human studies have already been performed, and demonstrated a technical success rate of 100% with no serious adverse events reported for EUS.53,54 Moreover, this systematic review and meta-analysis specifically aimed to provide real-world data to simulate clinical practice through subgroup analysis that included only needle types that are cur-
rently used in clinical practice. Despite the significant learning curve and inter-operator variability required to perform EUS, we are hopeful that the subgroup analysis will improve the generalizability of our results. While significant heterogeneity was noted in our meta-analysis and was not surprising given the cumulative nature of reporting results, the use of a prediction interval was employed to demonstrate the variability within real world clinical practice.²⁴,⁵⁵

In conclusions, EUSLB is a minimally invasive procedure that appears to be a safe and effective approach to obtain hepatic tissue. Although adequate needle size and tissue acquisition techniques for optimal EUS-FNA require further study, current data suggests that EUSLB is comparable to the alternative strategies of PCLB and TJLB. A cost-utility study to determine which modality is most cost-effective may be helpful to guide future decisions regarding diagnostic strategies. Future well-designed, prospective comparator studies are needed to determine which subset of patients may benefit most from EUSLB.

Conflicts of Interest

Marvin Ryou is a consultant for Medtronic/Covidien, Boston Scientific, Olympus, and Pentax. Harry R. Aslanian is a consultant for Boston Scientific, Olympus, Speaker for Cook, GI Supply. The other authors have no financial conflicts of interest.

Author Contributions
Conceptualization: Thomas R. McCarty, Ahmad Najdat Bazarbashi, Marvin Ryou, Harry R. Aslanian, Thiruvengadam Muniraj
Formal analysis: TRM
Writing-original draft: TRM
Writing-review & editing: ANB, MR, HRA, TM

ORCID

Thomas R. McCarty: https://orcid.org/0000-0003-4517-5261
Ahmad Najdat Bazarbashi: https://orcid.org/0000-0002-5830-9938
Basile Njei: https://orcid.org/0000-0003-0714-4368
Marvin Ryou: https://orcid.org/0000-0001-8120-6497
Harry R. Aslanian: https://orcid.org/0000-0002-9126-0451

REFERENCES


